In a phase II trial, the experimental small molecule MET inhibitor AMG 337 was investigated in patients with gastric/gastroesophageal junction/esophageal adenocarcinoma, and a FISH assay with MET/CEP7 ≥ 2.0 as a cut-off was used [41,42]. The gene discussed is MET; the disease is esophageal adenocarcinoma.